We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

183 hedge funds and large institutions have $2.57B invested in Acceleron Pharma in 2019 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 61 increasing their positions, 60 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more call options, than puts

Call options by funds: $20.4M | Put options by funds: $10.4M

84% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 19

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

35% more capital invested

Capital invested by funds: $1.9B → $2.57B (+$668M)

6% more funds holding

Funds holding: 172 → 183 (+11)

2% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 60

Holders
183
Holders Change
+11
Holders Change %
+6.4%
% of All Funds
3.61%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.12%
New
35
Increased
61
Reduced
60
Closed
19
Calls
$20.4M
Puts
$10.4M
Net Calls
+$9.96M
Net Calls Change
+$12.5M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$91.9M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$42.6M
3
HM
HealthCor Management
New York
+$14.7M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$10.1M
5
GLA
Great Lakes Advisors
Illinois
+$6.22M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$20.7M
2
FCM
Farallon Capital Management
California
-$18.2M
3
Alkeon Capital Management
Alkeon Capital Management
New York
-$16.7M
4
Franklin Resources
Franklin Resources
California
-$13.7M
5
AG
Artal Group
Luxembourg
-$13.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
WMSA
101
Weiss Multi-Strategy Advisers
New York
$901K +$524K +11,500 +209%
WG
102
Winton Group
United Kingdom
$883K +$759K +16,651 New
MLICM
103
Metropolitan Life Insurance Company (MetLife)
New York
$740K -$14.8K -324 -2%
Wolverine Trading
104
Wolverine Trading
Illinois
$727K +$630K +13,821 New
GCP
105
GSA Capital Partners
United Kingdom
$708K +$609K +13,357 New
LCM
106
Laurion Capital Management
New York
$696K +$279K +6,127 +88%
VEA
107
Virtus ETF Advisers
New York
$671K +$270K +5,927 +88%
JRP
108
Jasper Ridge Partners
California
$663K – – –
ZCA
109
Zeke Capital Advisors
Pennsylvania
$625K -$137K -3,003 -20%
ACM
110
AlphaCrest Capital Management
New York
$620K -$324K -7,100 -38%
Los Angeles Capital Management
111
Los Angeles Capital Management
California
$590K -$99.4K -2,180 -16%
NSEDCP
112
NJ State Employees Deferred Compensation Plan
New Jersey
$530K – – –
PNC Financial Services Group
113
PNC Financial Services Group
Pennsylvania
$458K +$33.4K +732 +9%
Bank of Montreal
114
Bank of Montreal
Ontario, Canada
$457K +$198K +4,339 +102%
Millennium Management
115
Millennium Management
New York
$447K -$1.51M -33,174 -80%
Two Sigma Advisers
116
Two Sigma Advisers
New York
$440K -$1.9M -41,600 -83%
First Trust Advisors
117
First Trust Advisors
Illinois
$429K +$369K +8,086 New
B
118
Bailard
California
$424K -$228K -5,000 -38%
AB
119
Amalgamated Bank
New York
$424K +$11.2K +245 +3%
FCMI
120
Foresite Capital Management I
California
$424K +$365K +8,000 New
SIM
121
Spark Investment Management
New York
$418K – – –
XK
122
Xact Kapitalforvaltning
Sweden
$415K – – –
HSBC Holdings
123
HSBC Holdings
United Kingdom
$406K +$107K +2,355 +45%
EGM
124
Engineers Gate Manager
New York
$405K +$348K +7,642 New
RJA
125
Raymond James & Associates
Florida
$392K +$775 +17 +0.2%
3 4
5
6 7

XLRN Hedge Fund Activity: Q4 2019 in Review

183 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2019, worth a combined $2.57B — up 35% from $1.9B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new XLRN positions and 19 closed out — a net gain of 16 holders — while 61 added to existing stakes and 60 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $91.9M. The largest seller was Great Point Partners, cutting an estimated $20.7M.

  • 183 institutional investors held Acceleron Pharma (XLRN) as of Q4 2019, up from 172 in Q3 2019.
  • Funds reported $2.57B of Acceleron Pharma stock for Q4 2019, up 35% quarter-over-quarter.
  • 35 funds opened new Acceleron Pharma positions in Q4 2019 and 19 closed out, a net change of +16 holders.
  • The largest Acceleron Pharma buyer in Q4 2019 was Fidelity Investments, an estimated $91.9M added.
  • The largest Acceleron Pharma seller in Q4 2019 was Great Point Partners, an estimated $20.7M sold.

Based on aggregated 13F filings for Q4 2019.